3-(1-(3-(1,3-benzothiazol-6-yl)propylcar bamoyl)cycloalkyl)propanoic acid derivatives as NEP inhibitors

Details for Australian Patent Application No. 2004220269 (hide)

Owner Pfizer, Inc.

Inventors Hepworth, David

Agent Allens Arthur Robinson

Pub. Number AU-A-2004220269

PCT Pub. Number WO2004/080985

Priority 0305916.9 14.03.03 GB; 0329143.2 16.12.03 GB

Filing date 9 March 2004

Wipo publication date 23 September 2004

International Classifications

C07D 277/64 Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

A61P 015/00 Drugs for genital or sexual disorders

A61K 031/428 - condensed with carbocyclic rings

Event Publications

1 September 2005 PCT application entered the National Phase

  PCT publication WO2004/080985 Priority application(s): WO2004/080985

20 March 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004220274-Allergen peptide fragments and use thereof

2004220266-S- [2-[(1-Iminoethyl)amino]ethyl]-2-methylL-cysteine maleate hydrochloride crystalline salt